Fundamental Analysis of Abcellera Biologics Inc - Growth / Value Index
ABCL - Valuation Highlights
Valuation Analysis
Book Value in last 3 years is trending up
Tsr Value Index - Very Poor Score of 9.38
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Price to Earning | -7.47 | -8.51 | -213.39 % | |
| Price to Book | 1.33 | 0.954 | -1.13 % | 0.892 |
| Price to Sales | 30.68 | 21.82 | 789.87 % | |
| Enterprise Value to EBITDA Multiple | -6.47 | -10.57 | -460.80 % |
ABCL - Profitability Highlights
Profitability Analysis
Piotroski F Score - Stable Value of 4.0
Tsr Profitability Index - Very Poor Score of 5.00
Very Low Dividend Yield of 0 %
Company Net profit is Negative for last 5 Quarters
Negative Net Margin MRQ
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Return On Equity | -12.52 | -11.21 | -187.19 % | -3.59 |
| Return On Asset | -13.00 | -8.68 | -184.36 % | -2.78 |
| Net Profit Margin | -410.47 | -256.28 | -884.79 % | -407.98 |
| Operating Profit Margin | -625.49 | -389.91 | -933.55 % | -551.48 |
| EBITDA Margin | -425.01 | -182.56 | -420.81 % | -483.50 |
Highlights
| Market Cap | 1111.52 M |
| Enterprise Value | 984362 K |
| Price/Book TTM | 1.33 |
| Outstanding Share | 294054 K |
| Float/ Outstanding Share | 65.35% |
| Dividend Yield | 0 % |
Share Holding
Guru Numbers
| Price/Graham No | 0 |
| Peter Lynch Ratio | 0 |
| Piotroski F Score | 4.00 |
| Altman Z Score | 2.62 |
| Sloan Ratio | -0.091 |
| Peter Lynch Fair Value | 0 |
ABCL - Growth Highlights
Growth Analysis
Tsr Growth Index - Poor Score of 26.72
Companies' sales dropped by 89.62 % from last year
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | 35788.00 K | 89.62 % | 8.44 % |
| Gross Profit | 29022.00 K | 88.34 % | 65.27 % |
| EBITDA | -152104.00 K | 133.30 % | 26.52 % |
| Net Profit | -146898.00 K | 181.47 % | 13.87 % |
| EPS | -0.506 | 188.19 % | NA |
ABCL - Stability Highlights
Stability Analysis
Cash ratio of 6.39
Company is unable to generate enough free cash to support the business.
Interest Coverage of 0
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ |
|---|---|---|---|
| Debt to Equity Ratio | 0.0053 | 18.05 % | 0.0049 |
| Cash Ratio | 6.39 | -14.70 % | |
| Quick Ratio | 7.32 | -15.45 % | 7.75 |
| Shareholders Equity | 77.44 | -3.25 % | |
| Debt to EBITDA | -0.067 | -431.21 % |
Historical Valuation Ratios of Abcellera Biologics Inc
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Abcellera Biologics Inc
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Abcellera Biologics Inc
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Abcellera Biologics Inc
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)